ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 145 filers reported holding ABCELLERA BIOLOGICS INC in Q4 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,116,665 | +75724.9% | 1,728,603 | +16.0% | 0.01% | -18.2% |
Q1 2024 | $6,748 | -19.0% | 1,489,603 | +2.1% | 0.01% | -15.4% |
Q4 2023 | $8,334 | +7.1% | 1,459,503 | -13.7% | 0.01% | 0.0% |
Q3 2023 | $7,783 | -52.5% | 1,692,053 | -33.3% | 0.01% | -45.8% |
Q2 2023 | $16,386 | -22.7% | 2,536,603 | -9.8% | 0.02% | -14.3% |
Q1 2023 | $21,199 | -1.4% | 2,811,503 | +32.5% | 0.03% | -3.4% |
Q4 2022 | $21,500 | -99.9% | 2,122,403 | -28.8% | 0.03% | -31.0% |
Q3 2022 | $29,480,000 | -31.4% | 2,980,803 | -26.2% | 0.04% | -17.6% |
Q2 2022 | $42,987,000 | +68.4% | 4,036,303 | +54.2% | 0.05% | +70.0% |
Q1 2022 | $25,522,000 | +231.0% | 2,617,603 | +385.5% | 0.03% | +200.0% |
Q4 2021 | $7,711,000 | +356.5% | 539,203 | +539.6% | 0.01% | +400.0% |
Q3 2021 | $1,689,000 | -81.0% | 84,300 | -79.1% | 0.00% | -81.8% |
Q2 2021 | $8,870,000 | – | 403,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Founders Fund VII Management, LLC | 3,773,530 | $28,452,416 | 91.13% |
Founders Fund Growth Management, LLC | 407,017 | $3,068,908 | 14.23% |
Gruss & Co., LLC | 167,500 | $1,262,950 | 7.99% |
HARVARD MANAGEMENT CO INC | 4,105,095 | $30,952,416 | 3.25% |
Belmont Capital, LLC | 510,000 | $3,845,400 | 3.18% |
Prosight Management, LP | 753,528 | $5,681,601 | 2.69% |
Intellectus Partners, LLC | 872,483 | $6,578,520 | 2.08% |
Casdin Capital, LLC | 2,520,000 | $19,000,800 | 1.56% |
GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $13,022,958 | 1.50% |
Orbimed Advisors | 4,180,768 | $31,522,991 | 0.62% |